<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885660</url>
  </required_header>
  <id_info>
    <org_study_id>SR-BE-001</org_study_id>
    <nct_id>NCT04885660</nct_id>
  </id_info>
  <brief_title>Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects</brief_title>
  <official_title>Bioequivalence Study of Compound Lisinopril Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Qingdao University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The bioavailability of compound lisinopril tablets (specification: lisinopril 10mg /&#xD;
      amlodipine 5mg) developed by Sichuan shangrui biomedical Co., Ltd. was compared with that of&#xD;
      reference compound lisinopril tablets (specification: lisinopril 10mg / amlodipine 5mg)&#xD;
      produced by Hungary Gedeon Richter Pharmaceutical Co., Ltd.The bioequivalence of single dose&#xD;
      of test preparation and reference preparation was evaluated in heathy subjects under fasting&#xD;
      and fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2018</start_date>
  <completion_date type="Actual">November 20, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluate the Cmax of Lenopril and amlodipine for test preparation and reference preparation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Therapeutic Equivalency</condition>
  <arm_group>
    <arm_group_label>Compound lisinopril tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single oral of Compound lisinopril tablets test formulation( Lisinopril 10mg/Levamlodipine besylate 5mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compound lisinopril tablets(Lisonorm®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single oral of Compound lisinopril tablets reference formulation( Lisinopril 10mg/Levamlodipine besylate 5mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>compound lisinopril tablet</intervention_name>
    <description>The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)</description>
    <arm_group_label>Compound lisinopril tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>compound lisinopril tablet(Lisonorm®)</intervention_name>
    <description>The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)</description>
    <arm_group_label>Compound lisinopril tablets(Lisonorm®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - 1.Healthy male and female aged over 18years 2.Subjects willing to provide written&#xD;
        informed consent and to adhere to protocol requirements 3.Subject's weight within normal&#xD;
        range according to normal values for Body Mass Index (19.00 to 26.00 kg/m2 (both&#xD;
        inclusive)), males with minimum of 50 kg weight, females with minimum of 45kg weight.&#xD;
&#xD;
        4.Subjects have not clinically significant abnormalities, including vital signs, physical&#xD;
        examinations, laboratory tests, and ECG as determined by clinical examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.History or presence of significant cardiovascular, Urogenital, pulmonary, hepatic,&#xD;
             renal, gastrointestinal, endocrine, immunological, dermatological, neurological or&#xD;
             psychiatric disease or disorder 2.Allergic constitution(Allergic to two or more&#xD;
             substances) or hypersensitivity to investigational product 3.History or presence of&#xD;
             significant gastrointestinal inflammation /ulcer. or other medical history affecting&#xD;
             drug absorption 4.Use of any drugs or herbal medicine within 14 days prior to the&#xD;
             first dose 5.Can not follow approved birth control methods (a double barrier method)&#xD;
             from the screening（Female subjects from two weeks prior to the screening） till 3&#xD;
             months after the last dose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 9, 2021</last_update_submitted>
  <last_update_submitted_qc>May 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

